Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

Leukemia volume 21, pages 151–157 (2007)Cite this article

Abstract

In multiple myeloma, deletion of chromosome 13 (del(13)) is associated with poor prognosis regardless of treatment. This study analyzed the impact of del(13) status on response and survival following treatment with either bortezomib or high-dose dexamethasone in patients in the SUMMIT and APEX trials. Additionally, matched-pairs subset analyses were conducted of patients with and without del(13), balanced for age and International Staging System parameters. In both SUMMIT and APEX, prognosis appeared to be poorer in bortezomib-treated patients with del(13) compared with patients with no del(13) by metaphase cytogenetics. In the SUMMIT and APEX matched-pairs analysis, response and survival appeared comparable in bortezomib-treated patients with or without del(13) by metaphase cytogenetics. However, patients with del(13) receiving dexamethasone in APEX appeared to have markedly decreased survival compared with those without del(13) by metaphase cytogenetics. These matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del(13) as an independent prognostic factor. However, sample sizes were very small; these findings require confirmation from further studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715–720.

    CAS  PubMed  Google Scholar 

  2. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101: 189–194.

    Article  CAS  PubMed  Google Scholar 

  3. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  4. Facon T, vet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.

    Article  CAS  PubMed  Google Scholar 

  5. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041–1047.

    Article  CAS  PubMed  Google Scholar 

  6. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.

    CAS  PubMed  Google Scholar 

  7. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659–2666.

    Article  CAS  PubMed  Google Scholar 

  8. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056–4061.

    Article  PubMed  Google Scholar 

  9. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and −17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366–3371.

    CAS  PubMed  Google Scholar 

  11. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925–1930.

    CAS  PubMed  Google Scholar 

  12. Fassas AB, Tricot G . Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients. Leuk Lymphoma 2004; 45: 1083–1091.

    Article  CAS  PubMed  Google Scholar 

  13. Shaughnessy Jr J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44–52.

    Article  PubMed  Google Scholar 

  14. Mani A, Gelmann EP . The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776–4789.

    Article  CAS  PubMed  Google Scholar 

  15. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  PubMed  Google Scholar 

  16. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172.

    Article  CAS  PubMed  Google Scholar 

  17. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    Article  CAS  PubMed  Google Scholar 

  18. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  PubMed  Google Scholar 

  19. Stewart AK, Fonseca R . Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339–6344.

    Article  CAS  PubMed  Google Scholar 

  20. Schreiber S, Ackermann J, Obermair A, Kaufmann H, Urbauer E, Aletaha K et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br J Haematol 2000; 110: 605–609.

    Article  CAS  PubMed  Google Scholar 

  21. Kaufmann H, Kromer E, Nosslinger T, Weltermann A, Ackermann J, Reisner R et al. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol 2003; 71: 179–183.

    Article  CAS  PubMed  Google Scholar 

  22. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73–77.

    Article  CAS  PubMed  Google Scholar 

  23. Hardan I, Rothman R, Gelibter A, Cohen N, Shimoni A, Sokolovsky M et al. Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis. Exp Hematol 2004; 32: 254–260.

    Article  CAS  PubMed  Google Scholar 

  24. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587–590.

    Article  CAS  PubMed  Google Scholar 

  25. Zavrski I, Naujokat C, Niemoller K, Jakob C, Heider U, Langelotz C et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003; 129: 383–391.

    Article  CAS  PubMed  Google Scholar 

  26. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006; 108: 2165–2172.

    Article  CAS  PubMed  Google Scholar 

  27. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  28. Laterveer L, Verdonck LF, Peeters T, Borst E, Bloem AC, Lokhorst HM . Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma. Blood 2003; 101: 1201–1202.

    Article  CAS  PubMed  Google Scholar 

  29. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4364.

    Article  CAS  PubMed  Google Scholar 

  30. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316–1319.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Millennium Pharmaceuticals Inc., Cambridge, MA, USA. We thank the patients for their participation in these trials, as well as the study nurses, clinical research associates, and all the SUMMIT and APEX investigators for their important contributions to the implementation and management of these studies.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, St Vincent's Comprehensive Cancer Center, New York, NY, USA

    S Jagannath

  2. Department of Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

    P G Richardson & K C Anderson

  3. Department of Hematology, Erasmus Medical Centre, Rotterdam, The Netherlands

    P Sonneveld

  4. Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY, USA

    M W Schuster

  5. Bone and Marrow Transplantation Program, Alta Bates Cancer Center, Berkeley, CA, USA

    D Irwin

  6. Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    E A Stadtmauer

  7. Service des Maladies du Sang, Hospital Claude Huriez, Lille, France

    T Facon

  8. Department of Hematology, Hotel Dieu Hospital, Nantes, France

    J-L Harousseau

  9. Department of Pathology, Tufts-New England Medical Center, Boston, MA, USA

    J M Cowan

Authors
  1. S Jagannath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P G Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M W Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Irwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E A Stadtmauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Facon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J-L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J M Cowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Jagannath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jagannath, S., Richardson, P., Sonneveld, P. et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21, 151–157 (2007). https://doi.org/10.1038/sj.leu.2404442

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404442

Keywords

This article is cited by

Search

Advanced search

Quick links